Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
LENG8 antisense RNA 1 (LENG8-AS1) is a primate-specific long non-coding RNA (lncRNA) gene that is transcribed as an antisense RNA from the LENG8 locus but does not code for a protein. It is classified as an antisense RNA and belongs to the broader family of long non-coding RNAs. LENG8-AS1 is believed to play a role in the regulation of neuronal identity and central nervous system function, likely through mechanisms typical of lncRNAs such as chromatin remodeling, transcriptional interference, or RNA-mediated gene silencing. There is emerging evidence that LENG8-AS1 and related antisense lncRNAs are involved in neurodegenerative diseases, including Alzheimer's disease, though precise roles and mechanisms remain under investigation. No drugs are currently known to target LENG8-AS1, and it is not considered a conventional therapeutic target such as a receptor, enzyme, or transporter. There are no reported biomarkers or safety concerns directly associated with LENG8-AS1.
Not established for drug targets; as a lncRNA may modulate gene transcription by antisense inhibition or epigenetic modification
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on LENG8 antisense RNA 1 (LENG8-AS1).